BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34782423)

  • 1. Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework.
    Bhatia R; Alcaniz Boada E; Bonde JH; Quint WGV; Xu L; Ejegod DM; Cuschieri K; Arbyn M
    J Clin Pathol; 2023 Mar; 76(3):172-176. PubMed ID: 34782423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
    Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
    J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework.
    Bhatia R; Boada EA; Bonde J; Quint W; Christiansen IK; Xu L; Ejegod DM; Moncur S; Cuschieri K; Arbyn M
    J Virol Methods; 2021 Aug; 294():114161. PubMed ID: 33895238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
    Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
    Dhillon SK; Cocuzza CE; Chung PYJ; Martinelli M; Giubbi C; Njoku RC; Bhatia R; Cuschieri K; Arbyn M
    J Med Virol; 2023 Jan; 95(1):e28417. PubMed ID: 36541733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
    Xu L; Oštrbenk A; Poljak M; Arbyn M
    J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
    Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
    J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.
    Cuschieri K; Geraets DT; Moore C; Quint W; Duvall E; Arbyn M
    J Clin Microbiol; 2015 Oct; 53(10):3272-9. PubMed ID: 26246482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
    Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
    J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Evaluation of INNO-LiPA HPV Genotyping
    Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
    Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
    J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
    Geraets DT; Cuschieri K; de Koning MN; van Doorn LJ; Snijders PJ; Meijer CJ; Quint WG; Arbyn M
    J Clin Microbiol; 2014 Nov; 52(11):3996-4002. PubMed ID: 25210073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework.
    Ejegod DM; Pedersen H; Quint W; Xu L; Arbyn M; Bonde JH
    J Virol Methods; 2021 Jun; 292():114118. PubMed ID: 33766660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human Papillomavirus.
    Bhatia R; Serrano I; Wennington H; Graham C; Cubie H; Boland E; Fu G; Cuschieri K
    J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29237790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening.
    Hesselink AT; Heideman DA; Berkhof J; Topal F; Pol RP; Meijer CJ; Snijders PJ
    J Clin Microbiol; 2010 Mar; 48(3):797-801. PubMed ID: 20042622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.
    Xu L; Oštrbenk Valenčak A; Poljak M; Arbyn M
    J Clin Microbiol; 2020 May; 58(6):. PubMed ID: 32245832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
    Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
    J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VALGENT: A protocol for clinical validation of human papillomavirus assays.
    Arbyn M; Depuydt C; Benoy I; Bogers J; Cuschieri K; Schmitt M; Pawlita M; Geraets D; Heard I; Gheit T; Tommasino M; Poljak M; Bonde J; Quint W
    J Clin Virol; 2016 Mar; 76 Suppl 1():S14-S21. PubMed ID: 26522865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay.
    Benoy I; Xu L; Vanden Broeck D; Poljak M; Oštrbenk Valenčak A; Arbyn M; Bogers J
    J Clin Virol; 2019 Nov; 120():57-62. PubMed ID: 31569008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.